Dr. Daniel Olson, MD
Claim this profileUniversity of Chicago Comprehensive Cancer Center
Studies Cancer
Studies Skin Cancer
6 reported clinical trials
7 drugs studied
Area of expertise
1Cancer
Stage III
Stage IV
Stage I
2Skin Cancer
Stage III
Stage IV
Stage I
Affiliated Hospitals
Clinical Trials Daniel Olson, MD is currently running
Immunotherapy + Chemotherapy
for Sarcoma
This phase II trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patients with undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma that has spread from where it first started to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's DNA and may kill tumor cells. It also blocks a certain enzyme needed for cell division and DNA repair. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding immunotherapy (pembrolizumab) to the standard chemotherapy (doxorubicin) may help patients with metastatic or unresectable UPS or a related poorly differentiated sarcoma live longer without having disease progression.
Recruiting2 awards Phase 310 criteria
INBRX-106 + Pembrolizumab
for Lung Cancer
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and antitumor activity of the combination of INBRX-106 and the anti-PD-1 CPI pembrolizumab (keytruda).
Recruiting1 award Phase 1 & 25 criteria
More about Daniel Olson, MD
Clinical Trial Related3 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Daniel Olson, MD has experience with
- Pembrolizumab
- TAC01-HER2
- ADP-A2M4CD8
- INBRX-106
- Nivolumab
- Paclitaxel
Breakdown of trials Daniel Olson, MD has run
Stomach Cancer
Gastric Cancer
Esophageal Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Daniel Olson, MD specialize in?
Daniel Olson, MD focuses on Cancer and Skin Cancer. In particular, much of their work with Cancer has involved Stage III patients, or patients who are Stage IV.
Is Daniel Olson, MD currently recruiting for clinical trials?
Yes, Daniel Olson, MD is currently recruiting for 2 clinical trials in Chicago Illinois. If you're interested in participating, you should apply.
Are there any treatments that Daniel Olson, MD has studied deeply?
Yes, Daniel Olson, MD has studied treatments such as Pembrolizumab, TAC01-HER2, ADP-A2M4CD8.
What is the best way to schedule an appointment with Daniel Olson, MD?
Apply for one of the trials that Daniel Olson, MD is conducting.
What is the office address of Daniel Olson, MD?
The office of Daniel Olson, MD is located at: University of Chicago Comprehensive Cancer Center, Chicago, Illinois 60637 United States. This is the address for their practice at the University of Chicago Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.